Eric D. Shaff Receives Stock Award at Seres Therapeutics Inc (MCRB) — SEC Form 4, Feb 08, 2022
SEC Form 4 · No Market Transaction
Stock Award
Compensation grant — no market purchase or sale.
Filing Lag
2 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Eric D. Shaff CIK 0001643734 |
Director
CEO
|
Eric D. Shaff at Seres Therapeutics Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$9,095
More from this insider at Seres Therapeutics Inc
| 2026-08-18 | Sell | -$1,197 | View |
| 2026-07-10 | Award | — | View |
| 2026-05-19 | Sell | -$1,950 | View |
| 2026-02-18 | Sell | -$2,194 | View |
| 2025-11-18 | Sell | -$3,754 | View |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.38 | 2022-02-04 | A - Award/Grant | 500,000 A | $0.00 | 2032-02-03 | 500,000 Common Stock | Direct |
Footnotes (1)
- F1
- The option will vest as to 25% of the shares on February 4, 2023. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Show more
Related filings at Seres Therapeutics Inc
Institutional Holders
13F holders · Jun 30, 2026
35
institutional managers reporting a position
Largest by reported value
- Flagship Pioneering Inc. $9.12M
- Vanguard Capital Management Llc $2.27M
- Marshall Wace, Llp $1.36M
Other insiders at Seres Therapeutics Inc
GET /v1/forms/4/0000899243-22-005315
API docs
View Original SEC Filing